CD22 and breast carcinoma: Our laboratory has also recently developed nanoparticles for selective uptake of CD22 overexpressing B-cell malignancies and HER2 overexpressing breast cancer, proving both to be other possible targets for liposomes designed through the same platform [52, 53].